Susquehanna International Group
GLUE icon

Susquehanna International Group’s Monte Rosa Therapeutics GLUE Stock Holding History

Susquehanna International Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$436K Sell
26,500
-136,200
-84% -$2.6M ﹤0.01% 10008
2025
Q4 		$2.55M Sell
162,700
-9,300
-5% -$125K ﹤0.01% 5163
2025
Q3 		$1.27M Buy
+172,000
New +$911K ﹤0.01% 6751
2024
Q3 		– Sell
-12,100
Closed -$45.3K – 12361
2024
Q2 		$45.3K Buy
12,100
+700
+6% +$3.57K ﹤0.01% 11456
2024
Q1 		$80.4K Sell
11,400
-73,200
-87% -$434K ﹤0.01% 11334
2023
Q4 		$478K Buy
+84,600
New +$332K ﹤0.01% 8779

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Susquehanna International Group's GLUE Position: Q1 2026 in Review

Susquehanna International Group increased its Monte Rosa Therapeutics (GLUE) stake by 127% in Q1 2026, buying an estimated $265K and bringing the position to 24,751 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #10164.

Susquehanna International Group first reported a position in GLUE in Q2 2022 and has held it in 10 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Susquehanna International Group held 24,751 shares of Monte Rosa Therapeutics worth $407K as of Q1 2026.
  • Susquehanna International Group bought 13,844 Monte Rosa Therapeutics shares in Q1 2026, an estimated $265K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10164 holding.
  • Susquehanna International Group first reported a position in Monte Rosa Therapeutics in Q2 2022 and has held it in 10 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.